Grundläggande statistik
| CIK | 1836517 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Medicus Sciences Acquisition Corp - Class A
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| February 12, 2024 |
SC 13G/A 1 schedule13gamsac021224.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Medicus Sciences Acquisition Corp. (Name of Issuer) Class A Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G5960S108 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filin |
|
| February 8, 2024 |
SC 13G/A 1 formsc13ga.htm FORM SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Medicus Sciences Acquisition Corp (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) G5960S108 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001- 40068 MEDICUS SCIENCES ACQUISITION CORP. (Exact name of registrant as |
|
| February 14, 2023 |
MSAC / Medicus Sciences Acquisition Corp. / GLAZER CAPITAL, LLC Passive Investment SC 13G 1 msac20221231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Medicus Sciences Acquisition Corporation (Name of Issuer) Class A ordinary shares, $0.0001 par value per share (Title of Class of Securities) G5960S108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check |
|
| February 14, 2023 |
EX-99.2 3 tm235349d5ex2.htm EXHIBIT 2 Exhibit 2 POWER OF ATTORNEY FOR CERTAIN REGULATORY FILINGS INCLUDING CERTAIN FILINGS UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND THE INVESTMENT ADVISERS ACT OF 1940 I, David E. Shaw, hereby make, constitute, and appoint each of: Edward Fishman, Julius Gaudio, Martin Lebwohl, Maximilian Stone, David Sweet, Nathan Thomas, and Eric Wepsic, acting individually, |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Medicus Sciences Acquisition Corp. (Name of Issuer) Class A Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G5960S108 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriat |
|
| February 14, 2023 |
MSAC / Medicus Sciences Acquisition Corp. / D. E. SHAW & CO, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm235349d5sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1) Under the Securities Exchange Act of 1934 Medicus Sciences Acquisition Corp. (Name of Issuer) Class A ordinary shares, par value $0.0001 per share (Title of Class of Securities) G5960S108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Stat |
|
| February 14, 2023 |
EX-99.1 2 tm235349d5ex1.htm EXHIBIT 1 Exhibit 1 POWER OF ATTORNEY FOR CERTAIN REGULATORY FILINGS INCLUDING CERTAIN FILINGS UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND THE INVESTMENT ADVISERS ACT OF 1940 I, David E. Shaw, hereby make, constitute, and appoint each of: Edward Fishman, Julius Gaudio, Martin Lebwohl, Maximilian Stone, David Sweet, Nathan Thomas, and Eric Wepsic, acting individually, |
|
| February 14, 2023 |
EX-99.3 4 tm235349d5ex3.htm EXHIBIT 3 Exhibit 3 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned Reporting Persons hereby agrees to the joint filing, along with all other such Reporting Persons, on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Class A |
|
| February 13, 2023 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2023 Medicus Sciences Acquisition Corp. (Exact name of registrant as specified in its charter) Cayman Islands 001-40068 N/A (State or other jurisdiction of incorp |
|
| February 13, 2023 |
Medicus Sciences Acquisition Corp. Announces Liquidation Exhibit 99.1 Medicus Sciences Acquisition Corp. Announces Liquidation New York, New York, February 13, 2023 — Medicus Sciences Acquisition Corp. (the “Company”) (Nasdaq: MSAC), announced today that due to its inability to consummate an initial business combination within the time period required by its amended and restated memorandum and articles of association (the “Charter”), the Board of Direct |
|
| February 10, 2023 |
SC 13G/A 1 m020123a.htm SCHEDULE 13G/A (AMENDMENT NO. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Medicus Sciences Acquisition Corp. (Name of Issuer) Class A ordinary shares, $0.0001 par value (Title of Class of Securities) G5960S108 (CUSIP Number) December 31, 2022 (Date of Event Which Require |
|
| January 24, 2023 |
SC 13G/A 1 msaca112423.htm COWEN FINANCIAL PRODUCTS LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Medicus Sciences Acquisition Corp. (Name of Issuer) Common stock (Title of Class of Securities) G5960S108 (CUSIP Number) December 30, 2022 (Date of Event which Requires Filing of this Statement) Che |
|
| January 18, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2023 Medicus Sciences Acquisition Corp. (Exact name of registrant as specified in its charter) Cayman Islands 001-40068 N/A (State or other jurisdiction of incorpo |
|
| November 14, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: |
|
| August 11, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| May 12, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-4006 |
|
| March 31, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40068 |
|
| March 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2022 Medicus Sciences Acquisition Corp. (Exact name of registrant as specified in its charter) Cayman Islands 001-40068 N/A (State or other jurisdiction of incorpora |
|
| March 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Medicus Sciences Acquisition Corp. (Name of Issuer) Common stock (Title of Class of Securities) G5960S108 (CUSIP Number) March 10, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| February 15, 2022 |
Regulation FD Disclosure, Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 15, 2022 Medicus Sciences Acquisition Corp. (Exact name of registrant as specified in its charter) Cayman Islands 001-40068 N/A (State or other jurisdiction of incorporation) |
|
| February 14, 2022 |
EXHIBIT I JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Medicus Sciences Acquisition Corp (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) G5960S108 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 14, 2022 |
MSAC / Medicus Sciences Acquisition Corp. / Third Point LLC - SCHEDULE 13G Passive Investment SC 13G 1 t50555075a.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Medicus Sciences Acquisition Corp. (Name of Issuer) Class A ordinary shares, $0.0001 par value (Title of Class of Securities) G5960S108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Stat |
|
| February 14, 2022 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) Exhibit 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned a |
|
| February 14, 2022 |
SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 1)* Medicus Sciences Acquisition Corp (Name of Issuer) Common Stock (Title of Class of Securities) G5960S116** (CUSIP Number) December 31, 2021 (Date of Event Whi |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 Medicus Sciences Acquisition Corp. (Name of Issuer) Class A ordinary shares, par value $0.0001 per share (Title of Class of Securities) G5960S 108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| February 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 8, 2022 Medicus Sciences Acquisition Corp. (Exact name of registrant as specified in its charter) Cayman Islands 001-40068 N/A (State or other jurisdiction of incorporation) |
|
| January 20, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Comm |
|
| January 18, 2022 |
Exhibit 1 POWER OF ATTORNEY FOR CERTAIN REGULATORY FILINGS INCLUDING CERTAIN FILINGS UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND THE INVESTMENT ADVISERS ACT OF 1940 I, David E. |
|
| January 18, 2022 |
Exhibit 2 POWER OF ATTORNEY FOR CERTAIN REGULATORY FILINGS INCLUDING CERTAIN FILINGS UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND THE INVESTMENT ADVISERS ACT OF 1940 I, David E. |
|
| January 18, 2022 |
Exhibit 3 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned Reporting Persons hereby agrees to the joint filing, along with all other such Reporting Persons, on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Class A ordinary shares, par value $0. |
|
| January 18, 2022 |
MSAC / Medicus Sciences Acquisition Corp. / D. E. SHAW & CO, L.P. - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Medicus Sciences Acquisition Corp. (Name of Issuer) Class A ordinary shares, par value $0.0001 per share (Title of Class of Securities) G5960S108 (CUSIP Number) January 7, 2022 (Date of Event Which Requires Filing of this Statement) Check the following box to designate the rule pursuant |
|
| December 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 2, 2021 Medicus Sciences Acquisition Corp. (Exact name of registrant as specified in its charter) Cayman Islands 001-40068 N/A (State or other jurisdiction of incorporation) |
|
| November 4, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001- |
|
| August 5, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Medicus Sciences Acquisition Corp (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) G5960S108 (CUSIP Number) July 26, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| May 24, 2021 |
Exhibit 4.2 Amendment to Warrant Agreement THIS AMENDMENT TO WARRANT AGREEMENT (this ?Amendment?) is made and entered into as of April 29, 2021, by and between Medicus Sciences Acquisition Corp., a Cayman Islands exempted company (the ?Company?), and Continental Stock Transfer & Trust Company, a New York limited purpose trust company, as warrant agent (in such capacity, the ?Warrant Agent?) and co |
|
| May 24, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-4006 |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: March 31, 2021 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on F |
|
| April 7, 2021 |
msacu-form25 |
|
| April 1, 2021 |
Exhibit 99.1 Medicus Sciences Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing April 5, 2021 New York, April 1, 2021 // - Medicus Sciences Acquisition Corp. (the ?Company,? or ?MSAC?) announced that, commencing April 5, 2021 (the ?Unit Separation Date?), the units sold in the Company?s initial public offering (the ?Units?) will no longer trad |
|
| April 1, 2021 |
Financial Statements and Exhibits, Other Events 8-K 1 tm2111538d18k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 1, 2021 Medicus Sciences Acquisition Corp. (Exact name of registrant as specified in its charter) Cayman Islands 001-40068 N/A (State or other j |
|
| March 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40068 MEDICUS SCIENCES |
|
| March 31, 2021 |
Exhibit 10.12 Second Amendment to Forward Purchase Agreement THIS SECOND AMENDMENT TO FORWARD PURCHASE AGREEMENT (this ?Second Amendment?) is made and entered into as of March 30, 2021, by and among Medicus Sciences Acquisition Corp., a Cayman Islands exempted company (the ?Company?), and Altium MSAC, LLC, a Delaware limited liability company, and Structure Alpha LLC, a Delaware limited liability |
|
| March 31, 2021 |
Description of Registered Securities.* Exhibit 4.5 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED As of March 26, 2021, Medicus Sciences Acquisition Corp. (?we,? ?our,? ?us? or the ?Company?) had the following three classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): (i) its units, cons |
|
| March 31, 2021 |
Exhibit 10.11 Amendment to Forward Purchase Agreement THIS AMENDMENT TO FORWARD PURCHASE AGREEMENT (this ?Amendment?) is made and entered into as of February 17, 2021, by and among Medicus Sciences Acquisition Corp., a Cayman Islands exempted company (the ?Company?), and Altium MSAC, LLC, a Delaware limited liability company, and Structure Alpha LLC, a Delaware limited liability company (each a ?P |
|
| March 1, 2021 |
Medicus Sciences Acquisition Corp. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Medicus Sciences Acquisition Corp. (Name of Issuer) Class A Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G5960S116** (CUSIP Number) February 18, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to des |
|
| February 26, 2021 |
EX-99.1 2 tm218097d1ex-1.htm EXHIBIT 1 EXHIBIT I JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1 (k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joi |
|
| February 26, 2021 |
SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. )* Medicus Sciences Acquisition Corp. (Name of Issuer) Class A Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G5960S116** (CUSIP Num |
|
| February 24, 2021 |
Financial Statements and Exhibits, Other Events 8-K 1 tm2038331d158k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 18, 2021 Medicus Sciences Acquisition Corp. (Exact name of registrant as specified in its charter) Cayman Islands 001-40068 N/A (State or ot |
|
| February 24, 2021 |
MEDICUS SCIENCES ACQUISITION CORP. Exhibit 99.1 MEDICUS SCIENCES ACQUISITION CORP. Page Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of February 18, 2021 F-3 Notes to Financial Statement F-4 F-1 Report of Independent Registered Public Accounting Firm To the Shareholders and the Board of Directors of Medicus Sciences Acquisition Corp. Opinion on the Financial Statement We have audited the accompanying |
|
| February 19, 2021 |
Exhibit 10.3 PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT THIS PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT (as it may from time to time be amended and including all exhibits referenced herein, this "Agreement"), dated as of February 15, 2021, is entered into by and between Medicus Sciences Acquisition Corp., a Cayman Islands exempted company (the "Company"), and Medicus Sciences Holdings LLC, a |
|
| February 19, 2021 |
Exhibit 10.6 Medicus Sciences Acquisition Corp. 152 West 57th Street, Floor 20 New York, New York 10019 February 15, 2021 Medicus Sciences Holdings LLC 152 West 57th Street, Floor 20 New York, New York 10019 Attn: Michael Castor Re: Administrative Support Agreement Ladies and Gentlemen: This letter agreement by and between Medicus Sciences Acquisition Corp. (the ?Company?) and Medicus Sciences Hol |
|
| February 19, 2021 |
Amended and Restated Articles of Association.(1) Exhibit 3.1 Registrar of Companies Government Administration Building 133 Elgin Avenue George Town Grand Cayman Medicus Sciences Acquisition Corp. (ROC #368534) (the "Company") TAKE NOTICE that by written resolution of the sole shareholder of the Company dated 2 February 2021 and effective on 12 February 2021, the following special resolution was passed: 1 Adoption of Amended and Restated Memorand |
|
| February 19, 2021 |
Medicus Sciences Acquisition Corp. Announces Pricing of $80,000,000 Initial Public Offering Exhibit 99.1 Medicus Sciences Acquisition Corp. Announces Pricing of $80,000,000 Initial Public Offering New York, February 15, 2021 // - Medicus Sciences Acquisition Corp. (the “Company,” or “MSAC”) announced today the pricing of its initial public offering of 8,000,000 units, at a price to the public of $10.00 per unit, for aggregate gross proceeds of $80,000,000. Each unit consists of (i) one C |
|
| February 19, 2021 |
Underwriting Agreement, dated February 15, 2021, by and between the Company and Maxim Group LLC. (3) Exhibit 1.1 8,000,000 Units Medicus Sciences Acquisition Corp. UNDERWRITING AGREEMENT February 15, 2021 MAXIM GROUP LLC 405 Lexington Avenue New York, NY 10174 As Representative of the Underwriters named on Schedule A hereto Ladies and Gentlemen: The undersigned, Medicus Sciences Acquisition Corp., a Cayman Islands corporation (?Company?), hereby confirms its agreement with Maxim Group LLC (herein |
|
| February 19, 2021 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of February 15, 2021, is made and entered into by and among Medicus Sciences Acquisition Corp., a Cayman Islands exempted company (the "Company"), Medicus Sciences Holdings LLC, a Delaware limited liability company (the "Sponsor"), Maxim Partners LLC ("Maxim") and the undersigned parties list |
|
| February 19, 2021 |
Exhibit 4.1 WARRANT AGREEMENT between MEDICUS SCIENCES ACQUISITION CORP. and CONTINENTAL STOCK TRANSFER & TRUST COMPANY Dated February 15, 2021 THIS WARRANT AGREEMENT (this ?Agreement?), dated February 15, 2021, is by and between Medicus Sciences Acquisition Corp., a Cayman Islands exempted company (the ?Company?), and Continental Stock Transfer & Trust Company, a New York limited purpose trust co |
|
| February 19, 2021 |
Exhibit 10.5 February 15, 2021 Medicus Sciences Acquisition Corp. 152 West 57th Street, Floor 20 New York, New York 10019 Re: Initial Public Offering Ladies and Gentlemen: This letter (this ?Letter Agreement?) is being delivered to you in accordance with the Underwriting Agreement (the ?Underwriting Agreement?) entered into by and between Medicus Sciences Acquisition Corp., a Cayman Islands exempt |
|
| February 19, 2021 |
Exhibit 10.4 PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT THIS PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT (as it may from time to time be amended and including all exhibits referenced herein, this ?Agreement?), dated as of February 15, 2021, is entered into by and between Medicus Sciences Acquisition Corp., a Cayman Islands exempted company (the ?Company?), and Maxim Partners LLC (the ?Purchas |
|
| February 19, 2021 |
Exhibit 10.1 INVESTMENT MANAGEMENT TRUST AGREEMENT This Investment Management Trust Agreement (this ?Agreement?) is made effective as of February 15, 2021 by and between Medicus Sciences Acquisition Corp., a Cayman Islands exempted company (the ?Company?), and Continental Stock Transfer & Trust Company, a New York limited purpose trust company (the ?Trustee?). WHEREAS, the Company?s registration s |
|
| February 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 15, 2021 Medicus Sciences Acquisition Corp. (Exact name of registrant as specified in its charter) Cayman Islands 001-40068 N/A (State or other jurisdiction of incorporation) |
|
| February 19, 2021 |
Exhibit 4.2 CONTINGENT RIGHTS AGREEMENT This Contingent Rights Agreement (this ?Agreement?) is made as of February 15, 2021 between Medicus Sciences Acquisition Corp., a Cayman Islands exempted company (the ?Company?), and Continental Stock Transfer & Trust Company, a New York limited purpose trust company, with offices at 1 State Street, New York, New York 10004 (the ?Rights Agent?). WHEREAS, the |
|
| February 19, 2021 |
Exhibit 99.2 Medicus Sciences Acquisition Corp. Announces Closing of $92,000,000 Initial Public Offering and Full Exercise of the Overallotment Option New York, February 18, 2021 // - Medicus Sciences Acquisition Corp. (the ?Company,? or ?MSAC?) announced today the closing of its initial public offering of 9,200,000 units, which included the full exercise of the underwriter?s over-allotment option |
|
| February 17, 2021 |
$80,000,000 Medicus Sciences Acquisition Corp. 8,000,000 Units TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(4) Registration No. 333-251674 PROSPECTUS $80,000,000 Medicus Sciences Acquisition Corp. 8,000,000 Units Medicus Sciences Acquisition Corp. is a newly organized blank check company incorporated as a Cayman Islands exempted company and incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganizati |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Medicus Sciences Acquisition Corp. (Exact Name of Registrant as Specified in Its Charter) Cayman Islands N/A (State of Incorporation or Organization) (I.R.S. Employer Identification No.) 152 West |
|
| February 10, 2021 |
February 10, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Medicus Sciences Acquisition Corp. Registration Statement on Form S-1 File No. 333-251674 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as |
|
| February 10, 2021 |
Medicus Sciences Acquisition Corp. 152 West 57th Street, Floor 20 New York, New York 10019 February 10, 2021 VIA EDGAR U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Ruairi Regan Re: Medicus Sciences Acquisition Corp. Registration Statement on Form S-1, as amended Filed December 23, 2020 File No. 333-251674 Dear Mr. Lopez: Pursuant to Rule 461 under th |
|
| February 3, 2021 |
Exhibit 10.10 FORWARD PURCHASE AGREEMENT This Forward Purchase Agreement (this “Agreement”) is entered into as of February 2, 2021, by and among Medicus Sciences Acquisition Corp., a Cayman Islands exempted company (the “Company”), and Altium MSAC, LLC, a Delaware limited liability company, and Structure Alpha LLC, a Delaware limited liability company (each a “Purchaser”, and collectively, the “Pu |
|
| February 3, 2021 |
Form of Private Placement Warrant Purchase Agreement between the Registrant and Maxim Group LLC** Exhibit 10.8 PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT THIS PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT (as it may from time to time be amended and including all exhibits referenced herein, this “Agreement”), dated as of [], 2021, is entered into by and between Medicus Sciences Acquisition Corp., a Cayman Islands exempted company (the “Company”), and Maxim Group LLC (the “Purchaser”). WHEREA |
|
| February 3, 2021 |
Form of Registration Rights Agreement among the Registrant and certain security holders** Exhibit 10.5 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of [], 2021, is made and entered into by and among Medicus Sciences Acquisition Corp., a Cayman Islands exempted company (the “Company”), Medicus Sciences Holdings LLC, a Delaware limited liability company (the “Sponsor”), [Maxim Partners LLC] (“Maxim”) and the undersigned parties listed unde |
|
| February 3, 2021 |
As filed with the U.S. Securities and Exchange Commission on February 2, 2021 Registration No. 333-251674 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Medicus Sciences Acquisition Corp. (Exact name of registrant as specified in its charter) Cayman Islands 6770 N/A (State or other jurisdic |
|
| February 3, 2021 |
Exhibit 4.5 CONTINGENT RIGHTS AGREEMENT This Contingent Rights Agreement (this “Agreement”) is made as of [], 2021 between Medicus Sciences Acquisition Corp., a Cayman Islands exempted company (the “Company”), and Continental Stock Transfer & Trust Company, a New York limited purpose trust company, with offices at 1 State Street, New York, New York 10004 (the “Rights Agent”). WHEREAS, the Company |
|
| February 3, 2021 |
Specimen Ordinary Shares Certificate. (2) Exhibit 4.2 SPECIMEN CLASS A ORDINARY SHARE CERTIFICATE NUMBER SHARES MEDICUS SCIENCES ACQUISITION CORP. INCORPORATED UNDER THE LAWS OF THE CAYMAN ISLANDS CLASS A ORDINARY SHARES SEE REVERSE FOR CERTAIN ABBREVIATIONS CUSIP G5960S 108 This Certifies that is the owner of FULLY PAID AND NON-ASSESSABLE CLASS A ORDINARY SHARES OF THE PAR VALUE OF US$0.0001 EACH OF MEDICUS SCIENCES ACQUISITION CORP. (TH |
|
| February 3, 2021 |
Exhibit 10.3 INVESTMENT MANAGEMENT TRUST AGREEMENT This Investment Management Trust Agreement (this “Agreement”) is made effective as of [], 2021 by and between Medicus Sciences Acquisition Corp., a Cayman Islands exempted company (the “Company”), and Continental Stock Transfer & Trust Company, a New York limited purpose trust company (the “Trustee”). WHEREAS, the Company’s registration statement |
|
| February 3, 2021 |
Specimen Unit Certificate. (2) Proof - tm2038331d9ex4-1.htm Exhibit 4.1 SPECIMEN UNIT CERTIFICATE NUMBER UNITS U- SEE REVERSE FOR CERTAIN ABBREVIATIONS MEDICUS SCIENCES ACQUISITION CORP. CUSIP G5960S 116 UNITS CONSISTING OF ONE CLASS A ORDINARY SHARE AND ONE-NINTH OF ONE REDEEMABLE WARRANT AND A CONTINGENT RIGHT TO RECEIVE ADDITIONAL WARRANTS, EACH WHOLE WARRANT ENTITLING THE HOLDER TO PURCHASE ONE CLASS A ORDINARY SHARE THIS C |
|
| February 3, 2021 |
Exhibit 10.4 Medicus Sciences Acquisition Corp. 152 West 57th Street, Floor 20 New York, New York 10019 [], 2021 Medicus Sciences Holdings LLC 152 West 57th Street, Floor 20 New York, New York 10019 Attn: Michael Castor Re: Administrative Support Agreement Ladies and Gentlemen: This letter agreement by and between Medicus Sciences Acquisition Corp. (the “Company”) and Medicus Sciences Holdings LLC |
|
| February 3, 2021 |
Form of Warrant Agreement between Continental Stock Transfer & Trust Company and the Registrant** Exhibit 4.4 WARRANT AGREEMENT between MEDICUS SCIENCES ACQUISITION CORP. and CONTINENTAL STOCK TRANSFER & TRUST COMPANY Dated [], 2021 THIS WARRANT AGREEMENT (this “Agreement”), dated [], 2021, is by and between Medicus Sciences Acquisition Corp., a Cayman Islands exempted company (the “Company”), and Continental Stock Transfer & Trust Company, a New York limited purpose trust company, as warrant |
|
| February 3, 2021 |
Form of Compensation Committee Charter** Exhibit 99.2 MEDICUS SCIENCES ACQUISITION CORP. COMPENSATION COMMITTEE CHARTER I. Purpose The Compensation Committee (the “Committee”) of the Board of Directors of Medicus Sciences Acquisition Corp. (the “Company”) shall have responsibility for the compensation of the Company’s executive officers, including the Company’s Chief Executive Officer (the “CEO”), and for incentive compensation, equity-b |
|
| February 3, 2021 |
Specimen Warrant Certificate. (2) Exhibit 4.3 [FACE] Number Warrants THIS WARRANT SHALL BE VOID IF NOT EXERCISED PRIOR TO THE EXPIRATION OF THE EXERCISE PERIOD PROVIDED FOR IN THE WARRANT AGREEMENT DESCRIBED BELOW MEDICUS SCIENCES ACQUISITION CORP. Incorporated Under the Laws of the Cayman Islands CUSIP G5960S 124 Warrant Certificate This Warrant Certificate certifies that , or registered assigns, is the registered holder of warra |
|
| February 3, 2021 |
Exhibit 10.7 PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT THIS PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT (as it may from time to time be amended and including all exhibits referenced herein, this “Agreement”), dated as of [], 2021, is entered into by and between Medicus Sciences Acquisition Corp., a Cayman Islands exempted company (the “Company”), and Medicus Sciences Holdings LLC, a Delaware |
|
| February 3, 2021 |
Exhibit 10.2 [], 2021 Medicus Sciences Acquisition Corp. 152 West 57th Street, Floor 20 New York, New York 10019 Re: Initial Public Offering Ladies and Gentlemen: This letter (this “Letter Agreement”) is being delivered to you in accordance with the Underwriting Agreement (the “Underwriting Agreement”) entered into by and between Medicus Sciences Acquisition Corp., a Cayman Islands exempted compan |
|
| February 3, 2021 |
Exhibit 14.1 MEDICUS SCIENCES ACQUISITION CORP. Code of Business Conduct and Ethics I. Introduction Medicus Sciences Acquisition Corp. (the “Company”) requires the highest standards of professional and ethical conduct from its employees, officers and directors. The Company’s reputation for honesty and integrity is key to the success of its business. The Company intends that its business practices |
|
| February 3, 2021 |
Form of Underwriting Agreement** Exhibit 1.1 8,000,000 Units Medicus Sciences Acquisition Corp. UNDERWRITING AGREEMENT February [], 2021 MAXIM GROUP LLC 405 Lexington Avenue New York, NY 10174 As Representative of the Underwriters named on Schedule A hereto Ladies and Gentlemen: The undersigned, Medicus Sciences Acquisition Corp., a Cayman Islands corporation (“Company”), hereby confirms its agreement with Maxim Group LLC (herein |
|
| February 3, 2021 |
Form of Audit Committee Charter** Exhibit 99.1 MEDICUS SCIENCES ACQUISITION CORP. AUDIT COMMITTEE CHARTER I. Purpose The Audit Committee (the “Committee”) of the Board of Directors (the “Board”) of Medicus Sciences Acquisition Corp. (the “Company”) shall provide assistance to the Board in fulfilling its legal and fiduciary obligations to oversee: (a) the quality and integrity of the financial statements and other financial informa |
|
| February 3, 2021 |
Form of Indemnity Agreement. (2) Exhibit 10.9 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of [ ], 2021, by and between Medicus Sciences Acquisition Corp., a Cayman Islands exempted company (the “Company”), and [ ] (“Indemnitee”). WHEREAS, highly competent persons have become more reluctant to serve publicly-held companies and corporations as directors, officers or in other capacities unless they are |
|
| February 3, 2021 |
Form of Amended and Restated Memorandum and Articles of Association** Exhibit 3.2 THE COMPANIES ACT (AS REVISED) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION OF MEDICUS SCIENCES ACQUISITION CORP. (adopted by special resolution dated [ ] 2021 and effective on [ ] 2021) THE COMPANIES ACT (AS REVISED) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION OF MEDICUS S |
|
| January 28, 2021 |
MEDICUS SCIENCES ACQUISITION CORP. 152 West 57th Street, Floor 20 New York, New York 10019 January 28, 2021 VIA EDGAR U.S. Securities and Exchange Commission Office of Real Estate & Construction 100 F Street, N.E. Washington, DC 20549 Attn: James Lopez, Legal Branch Chief Re: Medicus Sciences Acquisition Corp. Form S-1 filed December 23, 2020 File No. 333-251674 Dear Mr. Lopez: Medicus Sciences Ac |
|
| January 28, 2021 |
TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on January 28, 2021. Registration No. 333-251674 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Medicus Sciences Acquisition Corp. (Exact name of registrant as specified in its charter) Cayman Islands 6770 N/A (Stat |
|
| December 23, 2020 |
Exhibit 99.5 Consent to be Named as a Director Nominee In connection with the filing by Medicus Sciences Acquisition Corp. of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of Med |
|
| December 23, 2020 |
Consent of Christopher Kaster * Exhibit 99.4 Consent to be Named as a Director Nominee In connection with the filing by Medicus Sciences Acquisition Corp. of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of Med |
|
| December 23, 2020 |
Promissory Note, dated December 7, 2020, issued to Medicus Sciences Holdings LLC* EX-10.1 3 tm2038331d2ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 THIS PROMISSORY NOTE (“NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY |
|
| December 23, 2020 |
Power of Attorney (included in the signature page to this registration statement)* TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on December 23, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Medicus Sciences Acquisition Corp. (Exact name of registrant as specified in its charter) Cayman Islands 6770 N/A (State or other jurisdi |
|
| December 23, 2020 |
Consent of Kenneth Berkovitz * Exhibit 99.3 Consent to be Named as a Director Nominee In connection with the filing by Medicus Sciences Acquisition Corp. of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of Med |
|
| December 23, 2020 |
Memorandum and Articles of Association* Exhibit 3.1 Assistant Registrar THE COMPANIES LAW (2020 REVISION) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES MEMORANDUM AND ARTICLES OF ASSOCIATION OF MEDICUS SCIENCES ACQUISITION CORP. Assistant Registrar THE COMPANIES LAW (2020 REVISION) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES MEMORANDUM OF ASSOCIATION OF MEDICUS SCIENCES ACQUISITION CORP. 1The name of the Company is Medicus Science |
|
| December 23, 2020 |
EX-10.6 4 tm2038331d2ex10-6.htm EXHIBIT 10.6 Exhibit 10.6 Medicus Sciences Acquisition Corp. 152 West 57th Street, Floor 20 New York, New York 10019 December 6, 2020 Medicus Sciences Holdings LLC 152 West 57th Street, Floor 20 New York, New York 10019 RE: Securities Subscription Agreement Ladies and Gentlemen: Medicus Sciences Acquisition Corp., a Cayman Islands exempted company (the “Company”), i |
